Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?

Suppr

超能文献

作者信息

Maccarrone Mauro, Wang Haibin, Dey Sudhansu K

出版信息

Clin Endocrinol (Oxf). 2007 Mar;66(3):456-7. doi: 10.1111/j.1365-2265.2007.02760.x.

DOI:10.1111/j.1365-2265.2007.02760.x

PMID:17302885

Abstract

摘要

相似文献

Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?

Clin Endocrinol (Oxf). 2007 Mar;66(3):456-7. doi: 10.1111/j.1365-2265.2007.02760.x.

Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.

Obesity (Silver Spring). 2011 Jul;19(7):1325-34. doi: 10.1038/oby.2011.69. Epub 2011 Apr 7.

The safety of obesity drugs.

Expert Opin Drug Saf. 2007 Sep;6(5):475-6; author reply 477-8. doi: 10.1517/14740338.6.5.475.

End of the line for cannabinoid receptor 1 as an anti-obesity target?

Nat Rev Drug Discov. 2008 Dec;7(12):961-2. doi: 10.1038/nrd2775.

Cannabinoid receptor CB1 antagonists state of the art and challenges.

Vitam Horm. 2009;81:159-89. doi: 10.1016/S0083-6729(09)81007-8.

[Sleep disorders associated with treatment with rimonabant].

Rev Neurol. 2008;47(8):446.

Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.

J Clin Psychopharmacol. 2013 Feb;33(1):118-20. doi: 10.1097/JCP.0b013e3182793843.

Metabolic syndrome treatment strategies.

Pharmacotherapy. 2006 Dec;26(12 Pt 2):222S-226S. doi: 10.1592/phco.26.12part2.222S.

Rimonabant and progression of atherosclerosis in obese persons.

JAMA. 2008 Jul 16;300(3):280; author reply 280-1. doi: 10.1001/jama.2008.24.

Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?

Nat Clin Pract Cardiovasc Med. 2008 Oct;5(10):610-2. doi: 10.1038/ncpcardio1319. Epub 2008 Aug 12.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?

Clin Endocrinol (Oxf). 2007 Mar;66(3):456-7. doi: 10.1111/j.1365-2265.2007.02760.x.

Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.

Obesity (Silver Spring). 2011 Jul;19(7):1325-34. doi: 10.1038/oby.2011.69. Epub 2011 Apr 7.

The safety of obesity drugs.

Expert Opin Drug Saf. 2007 Sep;6(5):475-6; author reply 477-8. doi: 10.1517/14740338.6.5.475.

End of the line for cannabinoid receptor 1 as an anti-obesity target?

Nat Rev Drug Discov. 2008 Dec;7(12):961-2. doi: 10.1038/nrd2775.

Cannabinoid receptor CB1 antagonists state of the art and challenges.

Vitam Horm. 2009;81:159-89. doi: 10.1016/S0083-6729(09)81007-8.

[Sleep disorders associated with treatment with rimonabant].

Rev Neurol. 2008;47(8):446.

Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.

J Clin Psychopharmacol. 2013 Feb;33(1):118-20. doi: 10.1097/JCP.0b013e3182793843.

Metabolic syndrome treatment strategies.

Pharmacotherapy. 2006 Dec;26(12 Pt 2):222S-226S. doi: 10.1592/phco.26.12part2.222S.

Rimonabant and progression of atherosclerosis in obese persons.

JAMA. 2008 Jul 16;300(3):280; author reply 280-1. doi: 10.1001/jama.2008.24.

Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?

Nat Clin Pract Cardiovasc Med. 2008 Oct;5(10):610-2. doi: 10.1038/ncpcardio1319. Epub 2008 Aug 12.